BaseSpace
Correlation Engine 2.0
Import Your Data
Literature

FAQ

More FAQs

Back to top
Clear Search sequence regions
(e.g. Ciprofibrate, rs2300478, CXCL2, Metabolism of xenobiotics, Ischemia, Lymphocyte)
Bookmark Forward

In-vitro activity of the monobactam Ro 17-2301 against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

D A Bremner

The Journal of antimicrobial chemotherapy 1985 Oct


filter terms:
  • ampicillin (1)
  • antibiotics (1)
  • antibiotics (2)
  • aztreonam (4)
  • carumonam (1)
  • ceftazidime (2)
  • ceftriaxone (1)
  • cefuroxime (1)
  • enterobacteriaceae (4)
  • gentamicin (3)
  • humans (1)
  • in vitro (2)
  • infections (1)
  • lactams (2)
  • microbial sensitivity tests (1)
  • monobactam antibiotic (1)
  • pseudomonas aeruginosa (3)
  • pseudomonas infections (1)
  • ro 17-2301 (3)
    • Sizes of these terms reflect their relevance to your search.

    Ro 17-2301 is a monobactam antibiotic. Its in-vitro activity was compared with those of aztreonam, ampicillin, cefuroxime, ceftriaxone, ceftazidime, and gentamicin. Ro 17-2301 had qualitatively similar activity to aztreonam and activity superior to that all the other antibiotics against the Enterobacteriaceae, but against Pseudomonas aeruginosa ceftazidime had equal or marginally better activity.

    Citation

    D A Bremner. In-vitro activity of the monobactam Ro 17-2301 against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy. 1985 Oct;16(4):457-61

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 3934129

    View Full Text
    • Copyright © 2024 Illumina Inc. All rights reserved.